Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
GeneDx Holdings Corp (NASDAQ: WGS) closed the day trading at $109.84 down -7.88% from the previous closing price of $119.24. In other words, the price has decreased by -$7.88 from its previous closing price. On the day, 0.9 million shares were traded. WGS stock price reached its highest trading level at $121.0 during the session, while it also had its lowest trading level at $107.17.
Ratios:
For a better understanding of WGS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 20.47 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 205.23. For the most recent quarter (mrq), Quick Ratio is recorded 2.59 and its Current Ratio is at 2.71. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on October 20, 2025, initiated with a Buy rating and assigned the stock a target price of $155.
On July 09, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $110.
On May 15, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $88.Guggenheim initiated its Buy rating on May 15, 2025, with a $88 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 16 ’25 when Feeley Kevin sold 3,855 shares for $143.87 per share. The transaction valued at 554,616 led to the insider holds 8,731 shares of the business.
Stueland Katherine sold 10,857 shares of WGS for $1,562,185 on Dec 16 ’25. The CHIEF EXECUTIVE OFFICER now owns 14,237 shares after completing the transaction at $143.89 per share. On Dec 09 ’25, another insider, Feeley Kevin, who serves as the CHIEF FINANCIAL OFFICER of the company, sold 1,266 shares for $159.28 each. As a result, the insider received 201,648 and left with 5,389 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WGS now has a Market Capitalization of 3174880000 and an Enterprise Value of 3132962048. As of this moment, GeneDx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1821.56, and their Forward P/E ratio for the next fiscal year is 244.03. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.80. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.89 while its Price-to-Book (P/B) ratio in mrq is 10.86. Its current Enterprise Value per Revenue stands at 7.79 whereas that against EBITDA is 90.383.
Stock Price History:
The Beta on a monthly basis for WGS is 2.09, which has changed by 0.6467339 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, WGS has reached a high of $170.87, while it has fallen to a 52-week low of $55.17. The 50-Day Moving Average of the stock is -22.72%, while the 200-Day Moving Average is calculated to be 0.57%.
Shares Statistics:
Over the past 3-months, WGS traded about 510.79K shares per day on average, while over the past 10 days, WGS traded about 559910 shares per day. A total of 28.89M shares are outstanding, with a floating share count of 25.35M. Insiders hold about 12.28% of the company’s shares, while institutions hold 104.56% stake in the company. Shares short for WGS as of 1767139200 were 3072640 with a Short Ratio of 6.02, compared to 1764288000 on 3594043. Therefore, it implies a Short% of Shares Outstanding of 3072640 and a Short% of Float of 21.180001.
Earnings Estimates
. The current rating of GeneDx Holdings Corp (WGS) is the result of assessments by 7.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.02, with high estimates of $0.07 and low estimates of -$0.13.
Analysts are recommending an EPS of between $1.44 and $1.29 for the fiscal current year, implying an average EPS of $1.37. EPS for the following year is $0.44, with 7.0 analysts recommending between $0.74 and $0.05.
Revenue Estimates
8 analysts predict $120.49M in revenue. The current quarter. It ranges from a high estimate of $122.1M to a low estimate of $119.2M. As of. The current estimate, GeneDx Holdings Corp’s year-ago sales were $95.64MFor the next quarter, 8 analysts are estimating revenue of $117.5M. There is a high estimate of $119.6M for the next quarter, whereas the lowest estimate is $115.4M.
A total of 9 analysts have provided revenue estimates for WGS’s current fiscal year. The highest revenue estimate was $428.7M, while the lowest revenue estimate was $425.7M, resulting in an average revenue estimate of $427.04M. In the same quarter a year ago, actual revenue was $305.45MBased on 9 analysts’ estimates, the company’s revenue will be $531.02M in the next fiscal year. The high estimate is $545.6M and the low estimate is $521.7M.
